A Phase 1B/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Binimetinib With or Without Talazoparib in Patients With Locally Advanced or Metastatic RAS-Mutant Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Binimetinib (Primary) ; Talazoparib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 17 Aug 2019 Planned End Date changed from 12 Mar 2024 to 4 Oct 2023.
- 17 Aug 2019 Planned primary completion date changed from 14 Nov 2022 to 15 Mar 2022.
- 01 Jul 2019 Planned End Date changed from 1 Feb 2023 to 12 Mar 2024.